Detalhe da pesquisa
1.
Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question.
Br J Haematol
; 204(4): 1141-1142, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38429858
2.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
3.
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Br J Haematol
; 200(1): 45-53, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36205375
4.
Amyloidogenic light chains impair plasma cell survival.
Haematologica
; 108(12): 3359-3371, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381778
5.
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.
Haematologica
; 108(7): 1827-1839, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200421
6.
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma.
Eur J Haematol
; 110(4): 407-413, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36565290
7.
Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortality.
Eur J Haematol
; 111(1): 135-145, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37096337
8.
Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma.
Haematologica
; 107(10): 2395-2407, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35354252
9.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
10.
Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.
Acta Haematol
; 145(6): 642-649, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35933982
11.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
12.
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Eur J Haematol
; 106(2): 184-195, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33090552
13.
Neurological misdiagnoses of lymphoma.
Neurol Sci
; 42(5): 1933-1940, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32974798
14.
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Ann Hematol
; 99(6): 1273-1281, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32193630
15.
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
Am J Hematol
; 95(5): 465-471, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32048329
16.
Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients.
Ann Hematol
; 98(11): 2561-2567, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31515574
17.
Romidepsin-Bendamustine Combination for Relapsed/Refractory T Cell Lymphoma.
Acta Haematol
; 141(4): 216-221, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30943470
18.
The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis.
Br J Haematol
; 182(1): 86-92, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29767409
19.
Do older patients truly benefit from advances in myeloma care?
Haematologica
; 108(6): 1470-1472, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36300777
20.
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
Eur J Haematol
; 100(5): 494-501, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29453884